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Abstract
Background: Metastatic colorectal cancer carries a poor prognosis and cannot be cured by currently available
therapy. Chemotherapy designed to prolong survival and improve the quality of life (QOL) of patients is the mainstay of
treatment. Standard regimens of FOLFOX/bevacizumab and CapeOX/bevacizumab can cause neurotoxicity, potentially
disrupting treatment. The results of 3 phase II studies of combination therapy with S-1, irinotecan, and bevacizumab
showed comparable efficacy to mFOLFOX6/bevacizumab and CapeOX/bevacizumab, without severe neurotoxicity.
Therefore, the establishment and evaluation of S-1-containing irinotecan-based regimens for first-line treatment are
expected to become more important.
Methods: The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to
evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or
4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/
bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy. Patients
will be randomly assigned to either the control group (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) or study
group (SIRB or IRIS/bevacizumab). The target sample size is 450 patients. The primary endpoint is progression-free
survival (PFS), and the secondary endpoints are overall survival (OS), response rate (RR), time to treatment failure (TTF),
relative dose intensity (RDI), the incidence and severity of adverse events, quality of life (QOL), quality-adjusted life years
(QALY), health care costs, and relations between biomarkers and treatment response (translational research, TR).
Discussion: The results of this study will provide important information that will help to improve the therapeutic
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Background
Metastatic colorectal cancer carries a poor prognosis
and cannot be cured by currently available therapy.
Chemotherapy designed to prolong survival and improve
the quality of life (QOL) of patients is the mainstay of
treatment. On the basis of the results of previous clinical
studies [1–3], bevacizumab plus standard regimens such
as FOLFOX, CapeOX, and FOLFIRI is currently recom-
mended as first-line treatment for metastatic colorectal
cancer.
In Japan, S-1, an oral fluoropyrimidine-based antican-
cer preparation, is approved for the indication of
colorectal cancer. S-1 combines tegafur, a prodrug of 5-
fluorouracil, with 2 modulators of 5-fluorouracil metab-
olism: gimeracil and oteracil potassium. Gimeracil revers-
ibly inhibits dihydropyrimidine dehydrogenase (DPD), a
catabolic enzyme of 5-fluorouracil, and thereby increases
concentrations of 5-fluorouracil in serum and tumor
tissue. Oteracil potassium suppresses the activity of 5-
fluorouracil in gastrointestinal tissue, reducing gastrointes-
tinal toxicity [4]. Many clinical trials have evaluated S-1 in
combination with irinotecan. Komatsu et al. conducted
phase I/II studies in gastric cancer and phase II studies in
colorectal cancer [5, 6]. Subsequently, Muro et al.
performed a Phase II/III study (FIRIS trial) comparing
FOLFIRI with S-1/irinotecan (IRIS) as second-line therapy
in patients with metastatic colorectal cancer. IRIS was
demonstrated to be non-inferior to FOLFIRI in terms of
progression-free survival (PFS). IRIS was thus established
to be a viable option for the second-line treatment of
metastatic colorectal cancer, similar to FOLFIRI [7].
The results of phase II studies evaluating S-1 plus iri-
notecan combined with bevacizumab as first-line treat-
ment have been reported. In a study by Komatsu et al.
[8], bevacizumab (5 mg/kg) and irinotecan (100 mg/m2)
were given as a continuous intravenous infusion on days
1 and 15, and S-1 was given orally for 2 weeks, followed
by a 2-week rest period. This 4-week regimen was
regarded as 1 course. The RR was 57.7 % (95 % CI, 43.2
to 71.3 %), and the PFS was 16.7 months (95 % CI, 13.1
to 18.7 months). In a study performed by Yamada et al.
[9], bevacizumab (7.5 mg/kg) and irinotecan (150 mg/m2)
were given as a continuous intravenous infusion on
day 1, and S-1 was given orally for 2 weeks, followed
by a 1-week rest period. This 3-week regimen was
regarded as 1 course. The RR was 67.0 % (95 % CI,
52.1 to 79.1 %), and the PFS was 12.4 months (95 % CI,
10.0 to 14.7 months). Kato et al. [10] evaluated S-1
plus irinotecan combined with bevacizumab as first-
and second-line treatment. Bevacizumab (7.5 mg/kg)
and irinotecan (150 mg/m2) were given as a continu-
ous intravenous infusion on day 1, and S-1 was given
orally for 2 weeks, starting on day 3, every 3 weeks,
defined as 1 course. The RR was 72.0 % (95 % CI,
50.6 to 86.2 %), and the PFS was 11.5 months (95 % CI,
10.4 to 19.8 months).
The results of these studies demonstrated that a PFS
of 10 months can be expected with either a 4-week
course (IRIS/bevacizumab) or a 3-week course (SIRB) of
S-1 plus irinotecan combined with bevacizumab. Al-
though the dose of irinotecan in these regimens was
150 mg/m2 every 3 weeks, which is lower than the dose
in FOLFIRI (270 mg/m2 every 3 weeks), we considered
this dose of irinotecan to be appropriate for combination
therapy with S-1, irinotecan, and bevacizumab.
All studies of combination therapy with S-1, irinote-
can, and bevacizumab have confirmed that this regimen
is well tolerated: the incidence of grade 3 or higher neu-
tropenia was 14 to 27 %, and the incidence of grade 3 or
higher diarrhea was 7 to 17 %. Although some patients
had elevations of blood pressure or thrombosis (i.e., ad-
verse effects most likely attributed to bevacizumab),
concurrent treatment with bevacizumab did not in-
crease S-1- or irinotecan-related toxicity. The results
of these 3 phase II studies suggested that a combin-
ation of S-1, irinotecan, and bevacizumab (S-1/irinotecan/
bevacizumab) is comparable to FOLFOX/bevacizumab and
CapeOX/bevacizumab, currently used as standard regi-
mens for metastatic colorectal cancer, in terms of PFS. S-1/
irinotecan/bevacizumab can be given as a 3-week regimen
(SIRB) or a 4-week regimen (IRIS/bevacizumab).
Standard regimens of FOLFOX/bevacizumab and
CapeOX/bevacizumab can cause neurotoxicity, poten-
tially disrupting treatment. In the NO16966 study, the
PFS was 9.4 months in the FOLFOX/bevacizumab and
CapeOX/bevacizumab groups combined, as compared
with a time to treatment failure (TTF) of only 6.9 months.
The reason for treatment withdrawal was disease progres-
sion in 29 % of the FOLFOX/bevacizumab and CapeOX/
bevacizumab groups combined and adverse events in 32 %.
The main reasons for treatment withdrawal were not
adverse events caused by bevacizumab, but neuropathy
and other adverse events caused by chemotherapy. The
use of FOLFOX/CapeOX as first-line treatment is asso-
ciated with a higher total dose of oxaliplatin than
second-line treatment, resulting in a higher incidence
and severity of neuropathy [11]. In addition, the use of
these regimens as second-line treatment would prolong
exposure to neurotoxicity during the overall survival
period. Therefore, irinotecan-based chemotherapy should
be used as first-line treatment from the viewpoint of
toxicity and patients’ QOL. At present, oxaliplatin-
based regimens are mainly used for postoperative ad-
juvant chemotherapy. In patients who have recurrence
during or immediately after oxaliplatin-based chemo-
therapy, the cumulative neurotoxic effects of oxalipla-
tin may persist [12]. Therefore, the establishment and
evaluation of S-1-containing irinotecan-based regimens
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for first-line treatment are expected to become more
important.
On the basis of these findings, the primary end-
point of this study is to validate the non-inferiority
of combination therapy with S-1/irinotecan/bevacizumab
(SIRB or IRIS/bevacizumab) to oxaliplatin-based stand-
ard treatment (mFOLFOX6/bevacizumab or CapeOX/
bevacizumab) in terms of PFS and to assess superior-
ity if non-inferiority is demonstrated. Whether it is
possible to quantitatively predict differences in re-
sponse to irinotecan-based regimens and oxaliplatin-
based regimens will also be investigated, with the ul-
timate goal of improving patients’ QOL, healthcare
cost-performance, and individualized therapy of colo-
rectal cancer.
Methods and study design
Study design
This is a multicenter, randomized, open-label, controlled
phase III study of patients who receive first-line
treatment for metastatic colorectal cancer. The control
group will receive either mFOLFOX6/bevacizumab or
CapeOX/bevacizumab, preassigned according to institu-
tion (Fig. 1). The study group will receive either SIRB or
IRIS/bevacizumab. Patients will be randomly assigned to
either the control group or study group. Randomization
will be performed using a minimization method with the
following stratification factors: institution and the pres-
ence or absence of postoperative adjuvant chemotherapy
(none, postoperative adjuvant chemotherapy including
oxaliplatin, or postoperative adjuvant chemotherapy not
including oxaliplatin), and the number of metastatic or-
gans (1 vs. 2 or more).
Purpose of the study
This study is designed to validate the non-inferiority of
combination therapy with S-1/irinotecan/bevacizumab
(SIRB or IRIS/bevacizumab) to oxaliplatin-based stand-
ard treatment (mFOLFOX6/bevacizumab or CapeOX/
bevacizumab) in terms of PFS, the primary endpoint, in
patients with metastatic colorectal cancer who had not
received chemotherapy. Secondary endpoints are overall
survival (OS), response rate (RR), TTF, relative dose in-
tensity (RDI), the incidence and severity of adverse
events, QOL, quality-adjusted life years (QALY), health
care costs, and relations between biomarkers and treat-
ment response (translational research, TR).
Enrollment and allocation
Eligible patients will be randomly assigned to treatment
by means of a Web-based system managed by Medical
Toukei Corporation (Tokyo, Japan), independently from
the sponsor and participating institutions. Patients will
be randomly assigned to the control group (FOLFOX/
bevacizumab or CapeOX/bevacizumab) or study group
(SIRB or IRIS/bevacizumab) according to the pattern at
each institution (Fig. 2).
The main inclusion criteria are as follows: a histologi-
cally confirmed diagnosis of colorectal adenocarcinoma;
curatively unresectable, advanced or recurrent colorectal
cancer; an age of 20 years or older at enrollment; an
Eastern Cooperative Oncology Group performance sta-
tus (PS) of 0 or 1; confirmed presence of assessable
lesions on objective examinations such as computed
tomography, magnetic resonance imaging, and radiog-
raphy (measurable lesions not required); no history of
chemotherapy or radiotherapy (However, patients who
Fig. 1 Study schema
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had received postoperative adjuvant chemotherapy were eli-
gible provided that at least 180 days had elapsed since the
final day of treatment.); adequate oral intake; a leucocyte
count, ≥3000/μL; a neutrophil count, ≥1500/μL; a platelet
count, ≥100 × 103/μL; a hemoglobin level, ≥9.0 g/dL; a total
bilirubin level, ≤1.5 mg/dL; an aspartate aminotrans-
ferase(AST) level, ≤100 IU/L(≤150 IU/L in patients
with hepatic metastasis); an alanine aminotransferase(ALT)
level, ≤100 IU/L(≤150 IU/L in patients with hepatic metas-
tasis); a serum creatinine level, ≤1.2 mg/dL; a creatinine
clearance, ≥60 mL/min; an urinary protein level, ≤1+; an
expected survival of at least 3 months; and written in-
formed consent from the patient.
The main exclusion criteria are as follows: a history of
serious drug sensitivity; women who are pregnant or
may become pregnant; men who want their partner to
become pregnant; active infectious disease; serious com-
plications; marked electrocardiographic abnormalities or
clinically problematic heart disease; gastrointestinal ulcer
or bleeding; sensory neuropathy; serious diarrhea; ascites
or pleural effusion requiring treatment; gastrointestinal
obstruction; symptomatic peritoneal metastasis; brain
metastasis or brain metastasis suspected on the basis of
clinical symptoms; a history of gastrointestinal perfor-
ation within 6 months before enrollment (Patients with
gastrointestinal perforation due to obstructive colorectal
cancer are eligible.); a history of hemoptysis; a history
and complications of embolism, cerebral infarction
(Patients with asymptomatic lacunar infarction are
eligible.), lung infarction, or interstitial pneumonia; sur-
gery performed within 28 days before enrollment; con-
genital bleeding disorders or coagulation abnormalities;
treatment with anticoagulants; blood transfusion re-
quired within 14 days before enrollment; another active
cancer with a disease-free interval of less than 5 years;
continuous systemic treatment with steroids; positivity
for hepatitis B surface antigen; and patients considered




mFOLFOX6/bevacizumab regimen In patients assigned
to the mFOLFOX6/bevacizumab regimen, bevacizumab
(5 mg/kg) is given as a continuous intravenous infusion
over the course of 30 to 90 min on day 1, followed by a
continuous intravenous infusion of oxaliplatin (85 mg/m2)
plus l-leucovorin (200 mg/m2) given over the course of
2 h. Immediately after completing the infusion of oxalipla-
tin and l-leucovorin, 5-fluorouracil (400 mg/m2) is given
by rapid intravenous injection, followed by a continuous
intravenous infusion of 5-fluorouracil (2400 mg/m2), deliv-
ered with the use of an infusion pump over the course of
46 h. This 2-week course of treatment is repeated.
CapeOX/bevacizumab regimen In patients assigned
to the CapeOX/bevacizumab regimen, bevacizumab
(7.5 mg/kg) is given as a continuous intravenous in-
fusion over the course of 30 to 90 min on day 1,
followed by a continuous intravenous infusion of
oxaliplatin (130 mg/m2) over the course of 2 h. The
dose of capecitabine will be assigned according to
body surface area (BSA) as follows: BSA <1.36 m2,
2400 mg/day; BSA ≥1.36 m2 to <1.66 m2, 3000 mg/
day; BSA ≥1.66 m2 to <1.96 m2, 3600 mg/day; and
BSA ≥1.96 m2, 4200 mg/day. Capecitabine is given
orally twice daily after breakfast and dinner, starting
after dinner on day 1 to after breakfast on day 15,
followed by 14-day rest period. This 28-day regimen is
defined as 1 course of treatment and is repeated.
Treatment with the mFOLFOX6/bevacizumab regi-
men and CapeOX/bevacizumab regimen will be begun
in patients who meet all of the following criteria: leuco-
cyte count, ≥3000/μL; neutrophil count, ≥1500/μL;
platelet count, ≥100 × 103/μL; AST and ALT, ≤100 IU/L
(≤150 IU/L in patients with hepatic metastasis); total biliru-
bin level, ≤1.5 mg/dL; serum creatinine level, ≤1.2 mg/dL;
no fever of ≥38 °C suggesting infection; and ≤ grade 1 diar-
rhea and mucositis/stomatitis.
Fig. 2 Pattern of treatment at each institution
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Patients who have ≤ grade 2 neuropathy (sensory) will
receive 5-fluorouracil/l-leucovorin/oxaliplatin plus beva-
cizumab or CapeOX/bevacizumab. Patients with grade
3 neuropathy (sensory) will be given 5-fluorouracil/l–
leucovorin/bevacizumab or capecitabine/bevacizumab.
In patients with ≤ grade 1 hand-foot syndrome, treat-
ment will be started with the CapeOX/bevacizumab
regimen.
Dose-reduction criteria for the mFOLFOX6/bevaci-
zumab regimen and CapeOX/bevacizumab regimen
are as follows. In patients who have a leucocyte count
of <1000/μL, a neutrophil count of <500/μL, or a neu-
trophil count of <1500/μL on the day scheduled for the
next course of treatment to begin, and in those who
have ≥ grade 3 febrile neutropenia, a platelet count
of <50 × 103/μL, or AST and ALT levels of ≥200 IU/L, the
dose of 5-fluorouracil or the doses of capecitabine and
oxaliplatin are decreased by 1 level. In patients who
have ≥ grade 3 diarrhea, the dose of 5-fluorouracil is de-
creased by 1 dose level. In patients who have ≥ grade 3
diarrhea and hand-foot syndrome or 2 or more episodes of
grade 2 diarrhea and hand-foot syndrome, the dose of
capecitabine is decreased by 1 level. In patients who have a
platelet count of ≥50 × 103/μL or <75 × 103/μL, the dose
of only oxaliplatin is decreased by 1 level.
Study arms
SIRB regimen The SIRB regimen consists of bevacizu-
mab (7.5 mg/kg) given as a continuous intravenous infu-
sion over the course of 30 to 90 min on day 1, followed
by a continuous intravenous infusion of irinotecan
(150 mg/m2) given over the course of ≥90 min. The dose
of S-1 will be determined according to BSA as follows:
BSA <1.25 m2, 80 mg/day; BSA ≥1.25 m2 to <1.5 m2,
100 mg/day; and BSA ≥1.5 m2, 120 mg/day. S-1 is given
orally twice daily after breakfast and dinner, starting
from after dinner on day 1 to after breakfast on day 15,
followed by 7-day rest. This 21-day regimen is defined as
1 course of treatment and will be repeated.
IRIS/bevacizumab regimen The IRIS/bevacizumab
regimen consists of bevacizumab (5 mg/kg) given as a
continuous intravenous infusion over the course of 30 to
90 min on day 1 and day 15, followed by a continuous
intravenous infusion of irinotecan (100 mg/m2), given
over the course of ≥90 min. The dose of S-1 will be de-
termined according to BSA as follows: BSA <1.25 m2,
80 mg/day; BSA ≥1.25 m2 to <1.5 m2, 100 mg/day; and
BSA ≥1.5 m2, 120 mg/day. S-1 is given orally twice daily
after breakfast and dinner, starting from after dinner on
day 1 to after breakfast on day 15, followed by a 14-day
rest. This 28-day regimen is defined as 1 course of treat-
ment and will be repeated.
Treatment with the SIRB regimen and IRIS/bevacizu-
mab regimen is begun in patients who meet all of the
following criteria: leucocyte count, ≥3000/μL; neutrophil
count, ≥1500/μL; platelet count, ≥100 × 103/μL; AST
and ALT, ≤100 IU/L (≤150 IU/L in patients with hepatic
metastasis); total bilirubin level, ≤1.5 mg/dL; serum
creatinine level, ≤1.2 mg/dL; no fever of ≥38 °C sug-
gesting infection; and ≤ grade 1 diarrhea and mucositis/
stomatitis.
Dose-reduction criteria for the SIRB regimen and
IRIS/bevacizumab regimen are as follows. In patients
who have a leucocyte count of <1000/μL, a neutrophil
count of <500/μL, or a neutrophil count of <1500/μL on
the day scheduled for the next course of treatment to
begin, and in those who have ≥ grade 3 febrile neutro-
penia, a platelet count of <50 × 103/μL, AST and ALT
levels of ≥200 IU/L, or ≥ grade 3 diarrhea, the doses of
S-1 and irinotecan are each decreased by 1 level. In
patients who have a platelet count of ≥50 × 103/μL
or <75 × 103/μL, the dose of only oxaliplatin is de-
creased by 1 level. In patients who have a serum cre-
atinine level of ≥1.5 mg/dL or ≥ grade 3 mucositis or
stomatitis, the dose of S-1 is decreased by 1 level.
Withdrawal criteria Treatment in each group is re-
peated until patients meet the treatment withdrawal
criteria. The criteria for the withdrawal of the study
treatment are as follows: clear exacerbation of the pri-
mary disease; the subject requests discontinuation of the
study treatment; the attending physician judges that con-
tinuation of the study treatment is precluded by the de-
velopment of adverse events; it becomes difficult for the
subject to continuously consult the attending physician
because of changes in residence or hospitals or because
of other commitments; surgery is performed or consid-
ered feasible because of tumor shrinkage; patients are
found to be ineligible after enrollment; or the attending
physician judges that continuation of the study treat-
ment is precluded by other reasons.
Evaluation of treatment delivery and adverse events
Treatment delivery
Drug administration status such as dosage and the treat-
ment period will be recorded in the patients’ case report
forms. Whether treatment is temporarily withheld or the
dosage reduced and the reasons for such modifications
will also be recorded. Relative dose intensity (RDI) will
be calculated on the basis of these findings.
Safety profile
In this study, adverse events are followed up for 30 days
after the final dose of the study treatment or until the
start of subsequent therapy. Observed adverse events are
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evaluated according to the Common Terminology
Criteria for Adverse Events, version 4.0 (CTCAE, v4.0).
Statistical background
Definition of primary endpoint
The primary endpoint of the study is PFS. PFS is defined
as the period from the date of enrollment to the date of
disease progression or of death from any cause, which-
ever comes first. Data are censored on the date of
surgery for patients who undergo surgical resection of
tumors that respond to the protocol treatment and
become resectable. In patients with confirmed disease
progression (recurrence in patients who undergo R0
resection) after surgery, the confirmation date is consid-
ered to indicate an event.
Definition of analysis sets
The full analysis set (FAS) is defined as all enrolled
patients. However, patients with serious study protocol
violations (i.e., informed consent not obtained or serious
violations of the study procedures) will be excluded.
The per protocol set (PPS) is defined as the patients
remaining after exclusion of patients with serious vi-
olations of factors such the eligibility criteria, exclu-
sion criteria, or contraindicated drugs or therapy. The
safety analysis set (SAS) is defined as all enrolled patients
after excluding those who did not receive any of the study
treatment.
Definition of target sample size
On the basis of the results of the NO16966 study [2, 3],
the median PFS is estimated to be 11 months for
oxaliplatin-based regimens such as FOLFOX/bevacizumab
and CapeOX/bevacizumab and 12 months for S-1/
irinotecan/bevacizumab (hazard ratio, 0.917). Given
that the permissible limit for the hazard ratio is 1.25,
with a statistical power of 85 %, an alpha level of 0.025
(one-sided), an enrollment period of 36 months, and a
follow-up period of 18 months for the primary endpoint of
PFS, 434 patients are estimated to be required (required
number of events, 374). To compensate for ineligible
patients, the target number of patients is set at 450.
If the non-inferiority is demonstrated in the study,
superiority will be tested. (The enrollment of 434 pa-
tients is estimated to provide 78 % statistical power
to detect a difference between the groups with a haz-
ard ratio of 0.75).
Analysis plan
All evaluations of treatment effectiveness will be per-
formed in the FAS. As a reference, effectiveness will also
be analyzed in the PPS. Survival times (PFS, OS, and
TTF) are estimated by the Kaplan-Meier method. Two-
sided 95 % confidence intervals of the hazard ratios in
the assigned study groups are calculated by using a Cox
proportional-hazards model adjusted for stratification
factors other than institution and including only the
study group as a covariate. The upper limit of the confi-
dence interval will be confirmed to be below 1.25. Su-
periority in terms of PFS will be tested using a stratified
log-rank test adjusted for stratification factors other than
institution.
Response rates with confidence intervals will be calcu-
lated according to the assigned group for patients who
have measurable lesions. Differences in response rates
between assigned treatment groups will also be calcu-
lated along with the respective confidence intervals. The
best overall response rates will be calculated according
to the assigned group. A chi-square test (Fisher’s exact
test as needed) will be used to compare the assigned
groups.
To assess treatment achievement status, the RDI of
each drug used in each treatment group will be calcu-
lated, and summary statistics, including the medians and
means, will be reported. To evaluate safety, the inci-
dences of adverse events along with the confidence in-
tervals and grades will be calculated for each assigned
group. Chi-square tests (Fisher’s exact tests as required)
will be used to compare the assigned treatment groups.
Quality of life (QOL)
QOL variables will be evaluated with the use of the
Functional Assessment of Cancer Therapy–Colorectal
(FACT–C) [13], neurotoxicity subscale of the FACT/
Gynecology Oncology Group-Neurotoxicity (FACT/GOG-
Ntx) [14], QOL Questionnaire for Cancer Patients Treated
with Anticancer Drugs therapy (QOL-ACD) [15], and the
Japanese version of the EuroQol Group 5-Dimension Self-
Report Questionnaire (EQ-5D) [16]. Quality-adjusted life-
years (QALY) will be calculated on the basis of OS and the
utility values calculated from the results obtained for the 5
dimensions of EQ-5D.
QOL surveys will be performed before treatment,
16 weeks after treatment begins, 24 weeks after treat-
ment begins, and at the time of treatment withdrawal.
After withdrawal of the study treatment, only the FACT/
GOG-Ntx assessment will be performed 12 weeks and
24 weeks after the completion of treatment.
Cost-effectiveness analysis
Medical care costs required for the study treatment and
supportive care will be calculated for each course of
treatment per patient and compared between the control
group and the study group.
During the period from enrollment to completion of
the study treatment, data on the dose levels of each
drug, the number of administered doses, catheter place-
ment, port placement, methods for intravenous infusion
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management, methods for supportive care, and hospital
admissions will be collected and recorded in each pa-
tient’s case report form and used to calculate the cost
per course of treatment.
For patients treated at hospitals that cooperated in this
survey by providing the details of invoices for healthcare
remuneration (claim data), lifetime total medical care
costs will be calculated. For the period from initiation of
the study treatment until death, medical care costs ac-
cording to procedure and total medical care costs will be
calculated for each subject on a lifetime basis and during
the study treatment, and total medical care costs will be
compared between the control group and the study
group. In addition, after the study treatment begins, the
attending physician will fill in a patient questionnaire
concerning the use of nursing and long-term care ser-
vices, informal care provided by family members, and
disease-related changes in the employment status of the
patients and their family members. These data will be
used to compare non-medical care costs between the
control group and the study group.
The aforementioned data on medical care costs and
non-medical care costs and the QALY data will be used
to calculate incremental cost-effectiveness ratios in the
control group and the study group.
Translational research (TR)
Colorectal cancer can be broadly classified into 4 sub-
types according to two elements. Takahashi et al. reported
that the effectiveness of irinotecan-based regimens and
oxaliplatin-based regimens might differ according to sub-
type. For patients who participate in this study and consent
to providing tissue specimens, correlations of biomarkers
in histopathological specimens with outcomes and with
the clinical effectiveness of chemotherapy in this study will
be evaluated to determine whether the effectiveness of
irinotecan-based regimens and oxaliplatin-based regimens
can be predicted on the basis of subtype classifications de-
rived from comprehensive gene analysis. New biomarkers
will also be investigated.
The KRAS, NRAS, BRAF, and PIK3CA genes, CAC-
NA1G, IGF2, NEUROG1, RUNX3, SOCS1, and MLH1
as methylation markers for CpG island methylator
phenotype (CIMP), and other genes useful for the evalu-
ation of CIMP will be analyzed. Immunohistochemical
analyses of MLH1, MSH2, PMS2, MSH6, and PTEN will
be performed.
Ethical matters
This study will be conducted in accordance with the
Declaration of Helsinki and the ethical principles of
“Ethical Guidelines for Clinical Research” in Japan to
maximally ensure the human rights, welfare, and safety
of the subjects. Translational research variables evaluated
in this study will be evaluated according to “Ethical
Guidelines for Human Genome and Genetic Sequen-
cing Research.” Ethical approval has been obtained at
all participating centers Additional file 1: Table S1).
Decision criteria
Decision criteria will be determined by the steering
committee as follows. If S-1/irinotecan/bevacizumab
is demonstrated to be non-inferior in terms of the pri-
mary endpoint of PFS and is superior to mFOLFOX6/
bevacizumab or CapeOX/bevacizumab with respect to
one or more of the secondary endpoints of QOL, cost
performance, and the incidence of peripheral neuropathy,
S-1/irinotecan/bevacizumab will be comprehensively
evaluated to be positioned as a standard first-line treat-
ment for metastatic colorectal cancer, taking into account
the incidence and severity of adverse events as well as
other secondary endpoints.
If superiority is demonstrated in terms of PFS and the
incidence of serious adverse events is within acceptable
limits, S-1/irinotecan/bevacizumab will be positioned as
a standard treatment for metastatic colorectal cancer
from the time of this study.
Discussion
The present study is designed to comprehensively
analyze 2 regimens each in the control group and
the study group. Both mFOLFOX6/bevacizumab and
CapeOX/bevacizumab, used in the control group, are
standard treatments widely used in Japan. The results
of phase II studies of IRIS/bevacizumab and SIRB,
used in the study group, suggest that the efficacy and
side effect profiles of these regimens are generally
similar. Evidence from Phase III studies has been ob-
tained for IRIS/bevacizumab, but only the results of
phase II studies are available for SIRB. However, the
SIRB regimen has the advantage that patients are required
to come to the hospital only once every 3 weeks. Because
each regimen has advantages, 2 regimens are included in
the study arm of the present study.
At present, both oxaliplatin-based regimens and
irinotecan-based regimens are recommended as first-line
standard treatment for advanced or recurrent colorectal
cancer. In general clinical practice in Japan, oxaliplatin-
based regimens are usually used initially. However, given
the peripheral neuropathy associated with oxaliplatin,
first-line treatment with irinotecan-based regimens
might be better with respect to toxicity. In our study,
combining the oral preparation S-1 with irinotecan
instead of using FOLFIRI, a regimen combining intra-
venous 5-fluorouracil/l-leucovorin with irinotecan, is
expected to reduce drug-related costs and improve the
patients’ QOL because the use of a portable infusion
pump for 2 days is not required.
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In our study, the results of QOL surveys, translational
research, and cost effectiveness analysis are secondary
endpoints. We believe that our study is very meaningful
from the perspective of comparative effectiveness research.
Additional file
Additional file 1: Table S1. Ethic committee. (PPTX 81 kb)
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